Department of Nephrology, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-0051, Japan.
Clin Exp Nephrol. 2010 Oct;14(5):501-5. doi: 10.1007/s10157-010-0318-8. Epub 2010 Jul 23.
An elderly patient with pure red cell aplasia (PRCA) with antierythropoietin (anti-EPO) antibodies is described. PRCA due to alloimmunization is a rare and severe complication of recombinant human erythropoietin (rHu-EPO) therapy. Most reported patients with PRCA were cured primarily by immunosuppressive drug therapy. The patient in this case, however, did not want to receive any immunosuppressive drugs. Therefore, rHu-EPO injection was simply discontinued, the severe anemia gradually improved, and the hemoglobin approached normal range. This case is very rare and significant in that there have been few such elderly patients with rHu-EPO-induced PRCA in whom PRCA remission was achieved, with decreasing antibody titers, after cessation of rHu-EPO alone. Further cases are needed to assess how PRCA should be treated in patients with anti-EPO antibodies.
一位老年纯红细胞再生障碍性贫血(PRCA)伴抗促红细胞生成素(anti-EPO)抗体患者被描述。PRCA 是由同种免疫引起的,是重组人促红细胞生成素(rHu-EPO)治疗的一种罕见且严重的并发症。大多数报道的 PRCA 患者主要通过免疫抑制药物治疗得到治愈。然而,本病例中的患者不想接受任何免疫抑制剂治疗。因此,rHu-EPO 注射被简单地停止,严重的贫血逐渐改善,血红蛋白接近正常范围。该病例非常罕见且意义重大,因为在单独停止 rHu-EPO 治疗后,PRCA 缓解且抗体滴度降低的老年 rHu-EPO 诱导的 PRCA 患者中,很少有这样的患者。需要进一步的病例来评估在抗 EPO 抗体患者中应如何治疗 PRCA。